Product Name | CCT196969 |
Description |
RAF Inhibitor |
Purity | 96% |
CAS No. | 1163719-56-9 |
Molecular Formula | C27H24FN7O3 |
Molecular Weight | 513.53 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Blue Ice or 4ºC |
Product Type | Inhibitor |
Solubility | Soluble in DMSO |
Source | Synthetic |
Appearance | White Solid |
SMILES | CC(C)C)C1=NN(C2=CC=CC=C2)C(NC(NC(C(F)=C3)=CC=C3OC4=C5C(NC(C=N5)=O)=NC=C4)=O)=C1 |
Safety Phrases |
Classification: Caution: Substance not yet fully tested. Safety Phrases: S22 - Do not breathe dust S24/25 - Avoid contact with skin and eyes S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection |
Cite This Product | CCT196969 (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-185) |
Alternative Names | 1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)urea, CCT-196969, CCT 196969 |
Research Areas | Apoptosis, Cancer |
Scientific Background | CCT196969, a pan-RAF/SFK inhibitor is active against treatment-naive BRAF and NRAS mutant melanoma tumors. It is also active in tumors from patients who developed resistance to BRAF-selective inhibitors and a BRAF plus MEK inhibitor combination. IC50 0.1µM and 0.03µM for BRAF kinase and SRC kinase respectively. |
References | 1. Girotti, M.R., et al. (2015) Cancer Cell 27.1: 85-96. |
Reviews
There are no reviews yet.